Afficher la notice abrégée

Brain-immune crosstalk in the treatment of major depressive disorder

dc.rights.licenseopenen_US
dc.contributor.authorBRANCHI, Igor
dc.contributor.authorPOGGINI, Silvia
hal.structure.identifierNutrition et Neurobiologie intégrée [NutriNeuro]
dc.contributor.authorCAPURON, Lucile
IDREF: 167018736
dc.contributor.authorBENEDETTI, Francesco
dc.contributor.authorPOLETTI, Sara
dc.contributor.authorTAMOUZA, Ryad
dc.contributor.authorDREXHAGE, Hemmo
dc.contributor.authorPENNINX, Brenda W.J.H.
dc.contributor.authorPARIANTE, Carmine
dc.contributor.authorLEBOYER, Marion
dc.date.accessioned2021-09-21T12:09:26Z
dc.date.available2021-09-21T12:09:26Z
dc.date.issued2021-04
dc.identifier.issn0924-977Xen_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/112292
dc.description.abstractEnA growing number of studies are pointing out the need for a conceptual shift from a brain-centered to a body-inclusive approach in mental health research. In this perspective, the link between the immune and the nervous system, which are deeply interconnected and continuously interacting, is one of the most important novel theoretical framework to investigate the biological bases of major depressive disorder and, more in general, mental illness. Indeed, depressed patients show high levels of inflammatory markers, administration of pro-inflammatory drugs triggers a depressive symptomatology and antidepressant efficacy is reduced by excessive immune system activation. A number of molecular and cellular mechanisms have been hypothesized to act as a link between the immune and brain function, thus representing potential pharmacologically targetable processes for the development of novel and effective therapeutic strategies. These include the modulation of the kynurenine pathway, the crosstalk between metabolic and inflammatory processes, the imbalance in acquired immune responses, in particular T cell responses, and the interplay between neural plasticity and immune system activation. In the personalized medicine approach, the assessment and regulation of these processes have the potential to lead, respectively, to novel diagnostic approaches for the prediction of treatment outcome according to the patient's immunological profile, and to improved efficacy of antidepressant compounds through immune modulation.
dc.language.isoENen_US
dc.subject.enAntidepressants
dc.subject.enBrain-body
dc.subject.enImmunopsychiatry
dc.subject.enInflammation
dc.subject.enMetabolism
dc.subject.enNeural plasticity
dc.title.enBrain-immune crosstalk in the treatment of major depressive disorder
dc.typeArticle de revueen_US
dc.identifier.doi10.1016/j.euroneuro.2020.11.016en_US
dc.subject.halSciences du Vivant [q-bio]/Neurosciences [q-bio.NC]en_US
dc.identifier.pubmed33386229en_US
bordeaux.journalEuropean Neuropsychopharmacologyen_US
bordeaux.page89-107en_US
bordeaux.volume45en_US
bordeaux.hal.laboratoriesNutriNeurO (Laboratoire de Nutrition et Neurobiologie Intégrée) - UMR 1286en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINRAEen_US
bordeaux.teamPsychoneuroimmunologie et Nutrition: Approches expérimentales et cliniquesen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
bordeaux.identifier.funderIDBoehringer Ingelheimen_US
bordeaux.identifier.funderIDJohnson and Johnsonen_US
hal.exportfalse
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=European%20Neuropsychopharmacology&rft.date=2021-04&rft.volume=45&rft.spage=89-107&rft.epage=89-107&rft.eissn=0924-977X&rft.issn=0924-977X&rft.au=BRANCHI,%20Igor&POGGINI,%20Silvia&CAPURON,%20Lucile&BENEDETTI,%20Francesco&POLETTI,%20Sara&rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée